卡介苗无反应性非肌层浸润性膀胱癌的膀胱保留治疗:国际膀胱癌组织关于最佳顺序和患者选择的推荐
国际膀胱癌组织(IBCG)召集全球专家委员会,通过改良德尔菲流程制定卡介苗无反应性(BCG-U)非肌层浸润性膀胱癌(NMIBC)膀胱保留治疗(BST)的推荐,最终推荐在会议上达成>75%同意。推荐强调BST选择应个体化,并针对原位癌(CIS)和乳头状肿瘤分别给出推荐药物及顺序。
要点
- BCG-U NMIBC患者若希望避免根治性膀胱切除术(RC),目前尚无单一最佳药物。
- BCG-U CIS患者推荐吉西他滨/多西他赛(GEM/DOCE)、nadofaragene firadenovec(NFF)和nogapendekin alfa inbakicept-pmln(NAI)+BCG;因全身毒性,帕博利珠单抗仅在其他选择耗尽后提供。
- BCG-U乳头状肿瘤患者推荐GEM/DOCE、NFF、NAI+BCG、单药化疗、热灌注丝裂霉素C和帕博利珠单抗;鉴于疗效有限,鼓励参加临床试验。
核心结论
- IBCG共识推荐为BCG-U NMIBC的膀胱保留治疗提供了实用指导。
研究设计与样本
- 召集全球膀胱癌专家委员会,工作组回顾文献并制定推荐草案,由IBCG成员通过改良德尔菲流程投票,于2023年8月现场会议讨论并完善推荐,最终推荐在会议上达成>75%同意,部分推荐通过网络会议和电子邮件进一步完善。
主要发现
- 目前对于希望避免根治性膀胱切除术(RC)的BCG-U疾病患者,尚无单一最佳药物。
- BST选择应个体化,考虑患者个体特征和偏好、肿瘤属性以及可用药物的疗效/毒性数据。
- 对于BCG-U原位癌(CIS)患者,推荐吉西他滨/多西他赛(GEM/DOCE)、nadofaragene firadenovec(NFF)和nogapendekin alfa inbakicept-pmln(NAI)+BCG;因全身毒性,帕博利珠单抗仅在其他选择耗尽后提供。
- 对于BCG-U乳头状肿瘤患者,推荐GEM/DOCE、NFF、NAI+BCG、单药化疗、热灌注丝裂霉素C和帕博利珠单抗。
- 鉴于可用选择疗效有限,鼓励参加临床试验;对于已有数据但未获批的药物,IBCG推荐等待关键试验的最终结果。
关键数值与推荐
- BCG-U CIS患者推荐GEM/DOCE、NFF和NAI+BCG;帕博利珠单抗仅在其他选择耗尽后提供。
- BCG-U乳头状肿瘤患者推荐GEM/DOCE、NFF、NAI+BCG、单药化疗、热灌注丝裂霉素C和帕博利珠单抗。
- 最终推荐在会议上达成>75%同意。
临床怎么用
- BST选择应个体化,考虑患者个体特征和偏好、肿瘤属性以及可用药物的疗效/毒性数据。
- 对于BCG-U CIS患者,推荐GEM/DOCE、NFF和NAI+BCG;因全身毒性,帕博利珠单抗仅在其他选择耗尽后提供。
- 对于BCG-U乳头状肿瘤患者,推荐GEM/DOCE、NFF、NAI+BCG、单药化疗、热灌注丝裂霉素C和帕博利珠单抗。
- 鉴于可用选择疗效有限,鼓励参加临床试验。
- 对于已有数据但未获批的药物,IBCG推荐等待关键试验的最终结果。
局限性
- 目前缺乏关于膀胱保留治疗(BST)选项的随机试验。
- 目前对于希望避免根治性膀胱切除术(RC)的BCG-U疾病患者,尚无单一最佳药物。
- 可用选择的疗效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations for optimal selection of patients and therapies are urgently needed, especially in the absence of randomized trials on bladder-sparing treatment (BST) options. METHODS: A global committee of bladder cancer experts was assembled to develop recommendations on BST for BCG-U NMIBC. Working groups reviewed the literature and developed draft recommendations, which were then voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined on the basis of meeting discussions. Final recommendations achieved >75% agreement during the meeting, and some were further refined via web conferences and e-mail discussions. KEY FINDINGS AND LIMITATIONS: There is currently no single optimal agent for patients with BCG-U disease who seek to avoid radical cystectomy (RC). BST selection should be personalized, taking into account individual patient characteristics and preferences, tumor attributes, and efficacy/toxicity data for the agents available. For patients with BCG-U carcinoma in situ (CIS), gemcitabine/docetaxel (GEM/DOCE), nadofaragene firadenovec (NFF), and nogapendekin alfa inbakicept-pmln (NAI) + BCG are recommended; because of its systemic toxicity, pembrolizumab should only be offered after other options are exhausted. For patients with BCG-U papillary-only tumors, GEM/DOCE, NFF, NAI + BCG, single-agent chemotherapy, hyperthermic mitomycin C, and pembrolizumab are recommended. Given the modest efficacy of available options, clinical trial participation is encouraged. For unapproved agents with reported data, IBCG recommendations await the final results of pivotal trials. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BST for BCG-U NMIBC.
引用
- Li R, Hensley PJ, Gupta S, et al. Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024. PMID: 39183090. doi:10.1016/j.eururo.2024.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。